Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT04453813

PHASE3

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Sponsor: Sun Yat-sen University

View on ClinicalTrials.gov

Summary

Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of patients with unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with concurrent chemo-radiotherapy alone.

Official title: A Multicenter Randomized Clinical Phase 3 Trial of Toripalimab Plus Concurrent Chemo-radiotherapy vs Concurrent Chemo-radiotherapy Alone for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

226

Start Date

2020-07-03

Completion Date

2027-07

Last Updated

2020-09-28

Healthy Volunteers

Conditions

Nasopharyngeal Carcinoma Chemotherapy Radiotherapy PD-1 Treatment

Interventions

DRUG

Toripalimab plus concurrent chemo-radiotherapy

1. Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles). 2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks. 3. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy

DRUG

Concurrent chemo-radiotherapy

1. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks. 2. IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy

Inclusion Criteria: 1. Histologically confirmed recurrent nasopharyngeal carcinoma. 2. The recurrence time is more than 12 months from the end of the first course of radiotherapy. 3. Tumor staged as rT2-4N0-3M0，rII-IVa (according to the 8th AJCC edition). 4. Subjects must have a measurable disease by CT or MRI per RECIST 1.1 criteria. 5. Karnofsky scale (KPS)≥70. 6. Normal bone marrow function. 7. Normal liver and kidney function: 1. total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit; 2. creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit. 8. Given written informed consent. Exclusion Criteria: 1. Resectable nasopharyngeal diseases: rT2 (the tumour is confined in the superficial parapharyngeal spacer and is more than 0.5cm from the internal carotid artery) and rT3 (the tumour is confined in the base wall of the sphenoid sinus and is more than 0.5cm from the internal carotid artery and cavernous sinus). 2. The patients are suffering from severe nasopharyngeal necrosis, radiation induced brain injury, and fibrosis of the neck et. al, who are evaluated as unsuitable for secondary radiotherapy by the researchers. 3. Has known allergy to large molecule protein products or any compound of study therapy. 4. Has known subjects with other malignant tumors. 5. Has any active autoimmune disease or history of autoimmune disease. 6. Has a history of psychiatric substance abuse, alcoholism, or drug addiction. 7. The laboratory examination value does not meet the relevant standards within 7 days before enrollment 8. Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study medication. 9. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year. 10. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent. 11. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy). Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) will be allowed to enroll. 12. Has a known history of human immunodeficiency virus (HIV). 13. Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive 14. Has received a live vaccine within 4 weeks of planned start of study therapy 15. Pregnancy or breast feeding

Locations (6)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Cancer Center of Guangzhou Medical University

Guangzhou, Guangdong, China

Yuebei People's Hospital

Shaoguan, Guangdong, China

Zhongshan People's Hospital

Zhongshan, Guangdong, China

The Fifth Affiliated Hospital of Sun Yat-sen University

Zhuhai, Guangdong, China

Wuzhou Red Cross Hospital

Wuzhou, Guangxi, China